News from neuralstem, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Nov 17, 2014, 09:02 ET
Neuralstem Logo.

Neuralstem NSI-189 Phase Ib Major Depression Disorder Neurogenic Biomarker Data Presented At The CNS Summit

 Neuralstem, Inc. (NYSE MKT: CUR) announced that blood-based biomarkers for major depressive disorder (MDD) identified a rapid...

Nov 10, 2014, 09:00 ET
Neuralstem Logo

Neuralstem Announces Publication Of Long Term Cell Survival From Phase I NSI-566 ALS Study In The Journal "Annals Of Clinical And Translational Neurology"

Neuralstem, Inc. (NYSE MKT: CUR) announced the publication of results evaluating long term cell survival and differentiation of NSI-566...

Nov 07, 2014, 09:00 ET
Neuralstem Logo

Neuralstem Reports Third Quarter Financial Results And Provides Business And Clinical Update

 Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months and nine months ended September 30, 2014 and...

Oct 23, 2014, 09:15 ET
Neuralstem Logo.

Neuralstem Alzheimer's Disease Animal Data Presented At The Congress Of Neurological Surgeons Annual Meeting

Neuralstem, Inc. (NYSE MKT: CUR) announced that the first data in a study transplanting its neural stem cells in an animal model of...

Oct 09, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

First Patient Treated In Neuralstem Phase I Spinal Cord Injury Stem Cell Trial Through The UC San Diego Sanford Stem Cell Clinical Center

 Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated last week in the Phase I trial testing NSI-566 human neural...

Sep 22, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data

 Neuralstem, Inc. (NYSE MKT: CUR) announced that Jonathan D. Glass, MD, site investigator at Emory University, presented long-term follow up...

Sep 05, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem President And CEO To Present At The 2014 Rodman & Renshaw Annual Global Investment Conference

Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 16th Annual Rodman & Renshaw Global...

Aug 08, 2014, 08:00 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem Reports Second Quarter Financial Results And Provides Business And Clinical Update

 Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months and six months ended June 30, 2014 and provided a...

Aug 04, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Final Patient Treated In Neuralstem Phase II ALS Stem Cell Trial

 Neuralstem, Inc. (NYSE MKT: CUR) announced that the final patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural...

Jun 30, 2014, 09:15 ET

Neuralstem Added To Russell 3000 Index

 Neuralstem, Inc. (NYSE MKT: CUR) reports that its shares have been added to the broad-market Russell 3000® Index. Annual...

Jun 25, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem's NSI-189 Novel Neurogenic Compound Shows Significant Effect In Major Depressive Disorder

 Neuralstem, Inc. (NYSE MKT: CUR) announced that two sets of data from the NSI-189 clinical trial in major depressive disorder (MDD) were...

Jun 19, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem NSI-189 Select Data To Be Presented At Neuropsychopharmacology Congress

 Neuralstem, Inc. (NYSE MKT: CUR) announced that select data from the NSI-189 Phase Ib trial in patients with major depressive disorder (MDD)...

Jun 18, 2014, 09:15 ET

Neuralstem Final Phase I Depression Data Presented At The American Society Of Clinical Psychopharmacology Annual Meeting

 Neuralstem, Inc. (NYSE MKT: CUR)  announced that final data from the Neuralstem NSI-189 Phase Ib study in major depressive disorder (MDD)...

May 23, 2014, 09:28 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem Depression Trial Data to Be Presented at The American Society of Clinical Psychopharmacology Annual Meeting

 Neuralstem, Inc. (NYSE MKT: CUR) announced that data from the NSI-189 Phase Ib study in major depressive disorder (MDD) will be presented at...

May 16, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem CEO, Richard Garr, to Present at World Stem Cells & Regenerative Medicine Congress and Give Update on Trials

 Neuralstem, Inc. (NYSE MKT: CUR) CEO and President, Richard Garr, will present at the World Stem Cells & Regenerative Medicine Congress,...

May 12, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update

 Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months ended March 31, 2014 and provided a business and...

May 08, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem Appoints Sandford Drexel Smith, Former Genzyme Executive Vice President, To Board Of Directors

 Neuralstem, Inc. (NYSE MKT: CUR) announced the appointment of Sandford Drexel Smith to its Board of Directors, bringing the total number of...

Apr 16, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem Spinal Cord Injury Stem Cell Trial Approved To Commence At University Of California, San Diego

Neuralstem, Inc. (NYSE MKT: CUR) announced that the Institutional Review Board of the University of California, San Diego, School of Medicine has...

Apr 07, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Neuralstem Principal Investigator, Dr. Eva Feldman, To Present Published ALS Trial Phase I Data At Medical Conference

 Neuralstem, Inc. (NYSE MKT: CUR) announced that Eva Feldman, PhD, MD, principal investigator of Neuralstem's NSI-566 stem cell...

Mar 28, 2014, 09:15 ET
Neuralstem Logo. (PRNewsFoto/NEURALSTEM, INC.)

Study Shows Neuralstem Cells Transplanted Into Brain Significantly Improve Post-Stroke Symptoms in Rats

 Neuralstem, Inc. (NYSE MKT: CUR) announced that a study published in the peer-reviewed journal, PLOS ONE, showed that ischemic-stroke rats...